Preparing an injection from a bottle of VaxSyn, an experimental AIDS vaccine. VaxSyn is based on a genetically-engineered, recombinant form of the HIV protein gp160, which is a precursor to one of HIV's surface proteins. VaxSyn contains no attenuated infectious parts of HIV & therefore carries no risk of transmitting AIDS. The vaccine is being developed by MicroGeneSys and is undergoing trials as a treatment of HIV- positive patients & as a potential vaccine against HIV infection.
Model release not available. Property release not required.